IFN-alpha 2b/IFNA2 Protein, Human (HEK293, Fc)

IFN-alpha 2a, Human, a cytokine primarily produced by macrophages, displays robust antiviral activities. Its interaction with IFNAR2 is pivotal in mediating essential signaling pathways, contributing to intricate defense mechanisms against viral infections. IFN-alpha 2b/IFNA2 Protein, Human (HEK293, Fc) is the recombinant human-derived IFN-alpha 2b/IFNA2 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of IFN-alpha 2b/IFNA2 Protein, Human (HEK293, Fc) is 165 a.a., with molecular weight of 45-55 kDa.

IFN-alpha 2a, Human, is a cytokine primarily produced by macrophages, exhibiting robust antiviral activities. Its interaction with IFNAR2 plays a pivotal role in mediating essential signaling pathways, contributing to the intricate defense mechanisms against viral infections.

Measured by a cytotoxicity assay using TF-1 Cells. The ED₅₀ this effect is 23.61 pg/mL, corresponding to a specific activity is 4.235 ×10⁷ units/mg.

• 
  Measured by a cytotoxicity assay using TF-1 Cells. The ED₅₀ this effect is 23.61 pg/mL, corresponding to a specific activity is 4.235 ×10⁷ units/mg.

Human

HEK293

C-hFc

P01563 (C24-E188)

3440  [NCBI]

CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE

45-55 kDa

• 
  Greater than 95% as determined by reducing SDS-PAGE.

Lyophilized powder.

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.